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Abstract
Background: The ideal medication for treatment of acid related diseases should have a rapid
onset of action to promote hemostasis and resolution of symptoms. The aim of our study was to
investigate the inhibitory effects on gastric acid secretion after a single oral administrations of
lafutidine, is a newly synthesized H2-receptor antagonist, with mosapride 5 mg or lafutidine alone.
Methods: Ten Helicobacter pylori negative male subjects participated in this randomized, two-way
crossover study. Intragastric pH was monitored continuously for 4 hours after a single oral
administration of lafutidine 10 mg or lafutidine 10 mg with mosapride 5 mg (the lafutidine being
administrated one hour after the mosapride). Each administration was separated by a 7-day
washout period.
Results: The average pH during the 4-hour period after administration of lafutidine 10 mg with
mosapride 5 mg was higher than after lafutidine 10 mg alone (median: 5.25 versus 4.58, respectively;
p = 0.0318). During the 3–4 hour study period, lafutidine 10 mg with mosapride 5 mg provided a
higher pH, compared to lafutidine 10 mg alone (median: 7.28 versus 6.42; p = 0.0208).
Conclusion: In H. pylori negative healthy male subjects, an oral dose of lafutidine 10 mg with
mosapride 5 mg more rapidly increased intragastric pH than lafutidine 10 mg alone.
Background
The ideal medication for gastric acid related diseases,
especially for example hemorrhagic gastric ulcers and
stress related gastric bleeding, should have a rapid onset of
action to lower intragastric acidity, because in vitro studies
have shown that blood coagulation and platelet aggrega-
tion are abolished at a pH less than 5.4 [1]. Medication for
on-demand treatment also should have a rapid onset of
action to assure that symptoms are controlled. Multiple
agents including antacids, histamine H2 receptor antago-
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nists (H2RAs) and proton pump inhibitors (PPIs) are cur-
rently available. PPIs are the most potent inhibitors of
gastric acid secretion when used regularly [2]. However,
no study has yet examined whether an H2RA with mos-
apride (orally ingested) more rapidly increases intragastric
pH than the H2RA on its own. This crossover study was
designed to compare the acute effect on the intragastric
pH following administration of lafutidine 10 mg on its
own, or lafutidine 10 mg with mosapride 5 mg.
Methods
Subjects
This was a randomized, two-way crossover study with 10
healthy male volunteers, mean age 27.1 years (range 21 –
35 years), who were not users of acid suppressive medica-
tions including antacids, H2RAs, and/or PPIs. All subjects
were negative for anti-Helicobacter pylori (H. pylori) immu-
noglobulin G antibodies (SRL Inc, Tokyo, Japan).
Study Protocol and pH-metry
All subjects followed two study protocols in which they
were given 10 mg lafutidine (Protecadin, Taiho Pharma-
ceutical Co. Ltd, Tokyo, Japan) per os, or 10 mg lafutidine
and 5 mg mosapride (Gasmotin, Dainippon Sumitomo
pharmaceutical Co. Ltd, Osaka, Japan) with the lafutidine
being administrated one hour after the mosapride. Intra-
gastric pH was monitored continuously for 4 hours after
each protocol. There was a washout period of at least 7
days between each protocol. The subjects fasted overnight
(at least 8 hours) before each treatment protocol and dur-
ing the 4 hours after ingesting the drug or drugs, and both
experiments were performed in the morning.
The pH electrode was inserted transnasally under local
anaesthesia and located in the body of the stomach. The
gastric pH was measured at 10 second intervals by a port-
able pH meter attached to the antimony pH electrode
(Chemical Instrument Co. Ltd, Tokyo, Japan). The pH
electrode was calibrated before each recording using
standard buffers of pH 4.01 and 6.86. The pH data were
analyzed using established software (Chemical Instru-
ment Co. Ltd, Tokyo, Japan). The average pH and the per-
centage of times during which intragastric pH remained
above 1, 2, 3, 3.5, 4, 5, 6, 7 and 8 over the 4 hour moni-
toring period after the administration of each drug pro-
gramme were also measured.
Statistics
Statistical evaluation was carried out using the Wilcoxon
signed-ranks test. The level of significance was p < 0.05.
Statistical analyses were performed using the Stat View
program (SAS Institute, Cary, NC, USA).
Ethics
The study was conducted in accordance with the Declara-
tion of Helsinki, and the Ethics Committee of Yokohama
City University School of Medicine approved this study.
We obtained written informed consent from all volun-
teers.
Results
All subjects completed the study. No adverse events were
recorded during the study.
Average pH
The average pH during the 4-hour period after the admin-
istration of lafutidine 10 mg with mosapride 5 mg was
higher than after lafutidine 10 mg alone (median: 5.25
versus 4.58, respectively; p = 0.0318) (Figure 1).
The average pH was significantly higher after administra-
tion of lafutidine 10 mg with mosapride 5 mg, compared
to lafutidine 10 mg on its own during the 3–4 hour study
period (median: 7.28 versus 6.42; p = 0.0208) (Figure 2).
No significant differences were found at the 0–1, 1–2 and
2–3 hour study periods.
Holding time (%) of various pH levels over 4 hours
During the 4-hour study period, lafutidine 10 mg with
mosapride 5 mg provided longer durations of pH above 2,
3, 3.5, 4, 5, 6 and 7 than did lafutidine 10 mg alone
(median: 78.7% versus 75.6%; p = 0.5751, 70.8% versus
64.8%; p = 0.5071, 68.7% versus 59.9%; p = 0.1141,
67.6% versus 57.5%; p = 0.0593, 62.5% versus 49.8%; p
= 0.1394, 57.4% versus 43.9%; p = 0.1688, and 44.4%
versus 26.1%; p = 0.0284; respectovely) (Figure 3).
Discussion
In this study, we examined the change of intragastric pH
after a single oral administration of lafutidine 10 mg with
Average pH during the first 4 hours was higher after adminis- tration of lafutidine with mosapride than after lafutidine Figure 1
Average pH during the first 4 hours was higher after 
administration of lafutidine with mosapride than 
after lafutidine. *p = 0.0318 by the Wilcoxon signed-ranks 
test.
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mosapride 5 mg compared with lafutidine 10 mg alone in
the early post-administration phase in H. pylori negative
subjects.
Mosapride citrate (mosapride) (4-amino-5-chloro-2-
ethoxy-N-{[4-(4-fluorobenzyl)-2-morpholinyl]methyl}
benzamide citrate) is a novel gastrokinetic agent that
enhances gastrointestinal motility by stimulating the sero-
tonin (5-HT4) receptor [3]. Mosapride stimulates acetyl-
choline release from cholinergic neurons in the
gastrointestinal wall and may enhance upper gastrointes-
tinal motor activity in the postprandial state in conscious
dogs [4]. After oral administration, mosapride is absorbed
in the small intestine in rats, rather than the stomach [5].
Mosapride accelerates gastric emptying in healthy adults.
This study may indicate that mosapride accelerates the
absorption of lafutidine. For example, mosapride acceler-
ates the gastric emptying and completion rate of small
bowel examinations in patients undergoing capsule
endoscopy [6]. The time of gastric emptying time (GET) in
the mosapride group was reduced and indicated the obvi-
ous effect of mosapride on shortening GET. Moreover,
Preparation for barium enemas using mosapride before
and after oral intestinal lavage solution (PEG-ELS) intake
is more effective than the modified Brown's method that
is commonly used in Japan [7]. Mosapride improves gas-
trointestinal motility and reduces gastric stasis or gastro-
esophageal reflux [8,9]. Mosapride also alleviates
gastrointestinal dysfunction.
Although many factors are implicated in the development
of gastroesophageal reflux disease (GERD), acid reflux to
the esophagus is considered to be the major causes of this
disease. Treatment with PPIs to provide potent, long-term
suppression of gastric acid is essential for disease manage-
ment. On the other hand, the transient heartburn associ-
ated with mild GERD is attributed mainly to temporary,
short-term gastric acid reflux. For example, water and ant-
acid immediately increased gastric pH, while PPIs showed
a delayed but prolonged effect compared to H2RAs [10].
Because lafutidine promptly suppressed gastric acid secre-
rion [11], it was orginally considered to be a useful drug
for the on-demand treatment of mild GERD. Because
mosapride accelerates gastric emptying, Lafutidine can
pass from stomach to duodenum and be absorbed
quickly. Lafutidine used with mosapride may cause the
rapid onset of action, and may thus be more suitable for
on-demand use.
The limitation of the present study is that the data were
collected from healthy volunteers and not GERD patients
requiring on-demand therapy. The clinical implications of
our results remain unclear; however, our findings suggest
that the orally administered combination of lafutidine 10
mg preceded by mosapride 5 mg tablets may be suitable
for on-demand treatment in patients with GERD. Further
studies are necessary to confirm this assumption.
Conclusion
In H. pylori negative healthy male subjects, an oral dose of
lafutidine 10 mg with mosapride 5 mg more rapidly
increased intragastric pH than lafutidine 10 mg alone.
Lafutidine 10 mg with mosapride 5 mg provided a higher  average pH, compared to lafutidine 10 mg alone, at the 3–4  hour study period after administration Figure 2
Lafutidine 10 mg with mosapride 5 mg provided a 
higher average pH, compared to lafutidine 10 mg 
alone, at the 3–4 hour study period after administra-
tion. Squares (lafutidine with mosapride) and circles (lafuti-
dine), mean values; vertical lines, standard deviation (SD); 
horizontal line, ± SD. *p = 0.0208 by the Wilcoxon signed-
ranks test.
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During the 4-hour study period, lafutidine 10 mg with mos- apride 5 mg provided a longer duration of pH > 7, compared  to lafutidine 10 mg alone Figure 3
During the 4-hour study period, lafutidine 10 mg with 
mosapride 5 mg provided a longer duration of pH > 
7, compared to lafutidine 10 mg alone. Squares (lafuti-
dine with mosapride) and circles (lafutidine), mean values; 
vertical lines, standard deviation (SD); horizontal line, ± SD. 
*p = 0.0284 by the Wilcoxon signed-ranks test.
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